Publication date: Feb 05, 2025
Pneumonectomy, the surgical removal of an entire lung, was first performed in 1933 by Evarts A. Graham for lung carcinoma. Today, pneumonectomy is primarily indicated for non-small cell lung cancer (NSCLC) worldwide. However, it carries a higher risk of morbidity and mortality compared to less extensive lung resections. This study aims to investigate the indications for pneumonectomy and its short-term outcomes among patients who underwent the procedure between 2016 and 2023. A retrospective study was conducted on 112 patients who underwent pneumonectomy. Data were analyzed using the Statistical Package for the Social Sciences (SPSS) version 25. Univariate, bivariate, and multivariate analyses were performed to address the study’s objectives. The Pearson chi-square test, crude odds ratio (COR), and adjusted odds ratio (AOR) were calculated for categorical variables where appropriate. To identify factors associated with pneumonectomy, a binary logistic regression model was used, and odds ratios with 95% confidence intervals were calculated. A p-value of 180 min (AOR 37. 9; 95% CI: 1. 82, 792. 3). The morbidity rate was 25%, while the mortality rate was 5. 4%. In our setting, pneumonectomy is most commonly performed for inflammatory conditions. Significant factors associated with the procedure include a history of tuberculosis treatment, intraoperative blood loss > 500 mL, and surgical duration > 180 min. To reduce the need for pneumonectomy, strategies should focus on tuberculosis prevention, screening, and proper patient evaluation and diagnosis before treatment, to prevent extensive lung damage that often necessitates this procedure.
Concepts | Keywords |
---|---|
Extensive | Benign lung disease |
Pearson | Morbidity |
Pneumonectomy | Mortality |
Tuberculosis | Pneumonectomy |
Semantics
Type | Source | Name |
---|---|---|
drug | DRUGBANK | Nonoxynol-9 |
disease | MESH | non-small cell lung cancer |
pathway | KEGG | Non-small cell lung cancer |
disease | MESH | morbidity |
drug | DRUGBANK | Esomeprazole |
disease | IDO | history |
disease | MESH | tuberculosis |
pathway | KEGG | Tuberculosis |
disease | IDO | blood |
disease | MESH | lung disease |